Copyright
©The Author(s) 2023.
World J Crit Care Med. Sep 9, 2023; 12(4): 188-203
Published online Sep 9, 2023. doi: 10.5492/wjccm.v12.i4.188
Published online Sep 9, 2023. doi: 10.5492/wjccm.v12.i4.188
Biomarker | Diagnosis of sepsis | Differentiating sepsis and SIRS | Guiding antibiotic initiation | Organism identification |
Procalcitonin | Better than CRP; cannot be used independently; diagnosis based on clinical context | Better than CRP; cannot be used independently; diagnosis based on clinical context | Delays antibiotic administration; No short term mortality benefit | Higher in Gram negative bacteremia than Gram positive. Higher in bacteremia than in candidemia. No defined cutoffs. Treatment to be based on clinical judgement |
Presepsin | Possible role | Possible role | No significant data | No significant data |
nCD64 | Possible role; when combined with CRP, higher diagnostic accuracy and high negative predictive value | No significant data | No significant data | Increased in bacterial and viral infection more than fungal |
suPAR | Possible role | Performed poorly | No significant data | No significant data |
IL6 | Inferior to PCT, CRP | Inferior to PCT, CRP | No significant data | No significant data |
- Citation: Ahuja N, Mishra A, Gupta R, Ray S. Biomarkers in sepsis-looking for the Holy Grail or chasing a mirage! World J Crit Care Med 2023; 12(4): 188-203
- URL: https://www.wjgnet.com/2220-3141/full/v12/i4/188.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v12.i4.188